SNMMI meeting offers a special focus on radium-223 dichloride

05/21/2013 | MolecularImaging.net

A number of education sessions at this year's SNMMI Annual Meeting will focus on the newly approved radium-223 dichloride, a targeted radioisotope therapy for castrate-resistant prostate cancer, writes SNMMI Outreach Committee Co-chair Dr. Andrei Iagaru. "This is an exciting time for nuclear medicine as alpha radiation is not routinely used as a treatment. Preliminary results are encouraging and many [patient] and referring physician organizations have expressed interest in the new therapy," Iagaru writes.

View Full Article in:

MolecularImaging.net

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Compliance and Ethics Director
Sysmex America, Inc.
Lincolnshire, IL
Director, Site Quality Management
CareFusion
Palm Springs, CA
Compliance Officer-Medical Products
W. L. Gore
Flagstaff, AZ
Director, Site Quality Management
CareFusion
Minneapolis, MN
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC